Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.17 (
lysozyme
)
21,489
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Serum
lysozyme
has been demonstrated to be an indicator for macrophage activity in the tumor-bearing host. Therefore, we investigated
lysozyme
levels in the sera of 336 untreated tumor patients (121 malignant melanoma, 61 lung cancers, 70 cervical cancers, 49 breast cancers and 35 benign breast tumors, and 36 healthy controls). Patients with malignant melanoma and lung cancer had significantly higher
lysozyme
levels than the healthy controls. Within the clinical stages in melanoma, there was a decrease of
lysozyme
in stages II and III in comparison to stage I, but still above that of the control values. Patients with benign breast tumors had normal levels, whereas in
breast cancer
patients of stages I and II there was a significant reduction in the
lysozyme
levels. In stages III and IV no differences to the control group could be detected. In patients with cervical cancer (FIGO II and III) serum
lysozyme
levels were found to be within the normal range. From this study it can not be concluded that serum
lysozyme
reflects the immunological reactivity of the tumor bearer. Nevertheless, the reduced levels in stages I and II of
breast cancer
might point to an immunological defect.
...
PMID:Serum lysozyme levels in patients with solid tumors. 45 Mar 87
[We have measured four urinary nucleosides (dimethylguanosine, 1-methylinosine, pseudouridine and beta-aminoisobutyric acid)in patients with benign breast disease and patients with early and advanced
breast cancer
in order to assess their value as tumour-index-substances. We compared the results with other biochemical indices of
breast cancer
and sought and correlations between these indices. The results indicate that few abnormalities occurred in patients without overt metastases and these did not predict early relapse. In those with metastatic disease, dimethylguanosine excretion was most frequently elevated. Correlations were observed between some of the nucleosides and
lysozyme
and alpha1-antirypsin.
...
PMID:Nucleoside excretion in breast cancer: comparison with other biochemical tumour-index-substances. 51 4
Breast secretions can be classified into two types according to their major protein components. Type I fluids contain Zn-alpha 2-glycoprotein, apolipoprotein D, and gross cystic disease fluid protein-15, while Type II fluids are characterized by the presence of lactoferrin,
lysozyme
, and alpha-lactalbumin. In this study, the polypeptide composition of breast secretions from 719 nonlactating women was evaluated by using polyacrylamide gel electrophoresis. The required amount for the analysis (1 microliter) was obtained from 50% of control women and from 75% of women with mammary disease. There were more secretors in premenopausal than in postmenopausal women, as well as in parous than in nulliparous women. Evaluation of factors affecting protein composition of breast secretions revealed that Type II fluids were found in the majority of women who had given birth in the last four years and in a high proportion of oral contraceptive users. After excluding both of these groups, Type II fluids were detected in 47% of patients with
breast cancer
, but only in 8% of control women and in 16% of women with benign breast diseases. Taken together, these results suggest that protein analysis of breast secretions could be an useful tool for the study of breast pathologies.
Breast Cancer
Res Treat 1992
PMID:Factors affecting protein composition of breast secretions from nonlactating women. 146 65
We report here three cases of
breast cancer
with reactive multinucleated giant cells. The patients were among the 605 patients with
breast cancer
seen in the past 17 years at Tenri Hospital; the incidence of this variety of
breast cancer
was 0.5%. Enzyme histochemical and electron microscopic examination suggested that the giant cells were of histiocytic origin. However, results of immunohistochemical technique, S-100 protein,
lysozyme
, nonspecific cross-reacting antigen with carcinoembryonic antigen, alpha-1-antitrypsin, and alpha-1-antichymotrypsin, all currently used as markers of histiocytes, were negative. Because of the rarity of this variety of
breast cancer
, the biological significance of these unusual findings remains unknown.
...
PMID:Breast cancer with reactive multinucleated giant cells: report of three cases. 301 34
Elastosis associated with invasive ductal and lobular carcinomas of the breast was examined by tinctorial and immunohistochemical staining methods, enzyme digestion, and electron microscopy. The elastotic material exhibited the tinctorial staining properties of elastic fibres, and the ultrastructural appearances were those of elastic fibres although there was a higher proportion of microfibrils than in normal mature elastic fibres. The elastosis was immunostained by antisera to human fetal elastin,
lysozyme
and amyloid P component, as in other sites where elastic fibres are found. These findings indicate that immunohistochemically intact elastic fibres are present in the elastosis of
breast cancer
. They also demonstrate that
lysozyme
and amyloid P component are co-distributed with elastic fibres in elastosis of breast carcinoma, as distinct components with different susceptibilities to enzyme digestion. The cellular origin of elastosis in breast carcinoma remains uncertain.
...
PMID:Elastosis in breast carcinoma: I. Immunohistochemical characterization of elastic fibres. 303 89
We have investigated the influence of the 5'-flanking region of the chicken
lysozyme
gene on steroid dependent gene expression. By transient transfection of
lysozyme
-CAT fusion genes into the human
breast cancer
cell line T-47D, a DNA element was identified which stimulates CAT expression when transfected cells are treated with progesterone. This element is distinct from a second hormone responsive element (HRE) located in the
lysozyme
promoter region; it activates the
lysozyme
and the TK promoter, irrespective of orientation and distance, and is therefore referred to as hormone responsive element on its own. The location of this newly discovered HRE between -2250 and -1815 relative to the transcriptional start site, corresponds to the position of a steroid inducible DNase I-hypersensitive site in chromatin of oviduct cells. This observation suggests a physiological role for the upstream element. In vitro DNase I protection experiments revealed six binding sites for both progesterone and glucocorticoid receptors within the sequences of the upstream HRE. The three distal binding sites are not required for hormonal stimulation of the TK promoter, while the three proximal binding sites, which are contiguously arranged, work in a cooperative manner.
...
PMID:A progesterone responsive element maps to the far upstream steroid dependent DNase hypersensitive site of chicken lysozyme chromatin. 341 33
Cell suspensions from 16 tumour-free axillary lymph nodes from
breast cancer
patients were prepared, using collagenase digestion to free the sinus histiocytes from the fibrous stroma of the nodes. The histiocytic cells so obtained were then characterized using four surface markers: Fc(IgG) receptors, C3 receptors, DR antigen and a macrophage-associated antigen (defined by the monoclonal antibody VEP-7). In addition phagocytosis was assessed using IgG-coated red cells, and both
lysozyme
and alpha-1-antitrypsin were localized by means of immunoperoxidase staining. The results demonstrated that the majority of sinus histiocytes carried surface macrophage markers, but that a minority displayed phagocytosis and the presence of
lysozyme
or alpha-1-antitrypsin.
...
PMID:Sinus histiocytes in axillary lymph nodes from patients with breast cancer: macrophage characteristics and activation level. 351 7
Migration, phagocytosis and
lysozyme
production of peripheral monocytes from 36 patients with breast carcinoma was compared with a group of 36 healthy controls. A significant reduction in monocyte random migration and migration towards a chemotactic agent (P less than 0.001) was observed in patients with
breast cancer
. Furthermore monocyte phagocytic activity was also significantly decreased (P less than 0.001) in
breast cancer
patients compared to the controls. In contrast
lysozyme
production by peripheral monocytes was significantly increased in patients with
breast cancer
compared to controls (P less than 0.001). The changes in monocyte function in patients with breast carcinoma were not due to abnormal blood biochemistry or to direct continuous serum inhibitors, suggesting that the defect may be intrinsic. This defect in monocyte function may play an important role in the control of malignancies by cellular immune processes.
...
PMID:Alteration in monocyte function in patients with breast cancer. 366 57
The
lysozyme
content of tumor-infiltrating macrophages (TIM) from human breast carcinomas has been compared with that of blood monocytes both from
breast cancer
patients and tumor-free controls. Cells were identified as macrophages or monocytes with the use of rosetting reactions to detect receptors for the Fc portion of IgG and differentiation antigens, and
lysozyme
was detected by an immunoperoxidase technique on cytocentrifuge preparations of rosetted cells. Significantly more monocytes from patients with
breast cancer
contained
lysozyme
than monocytes from comparable controls, suggesting the presence of activated circulating blood monocytes. Conversely, TIM were virtually devoid of
lysozyme
. This lack of enzyme was not due to methodologic factors and may represent defective antitumor activity.
...
PMID:Blood monocytes and tumor-infiltrating macrophages in human breast cancer: differences in activation level as assessed by lysozyme content. 631 13
In 37 patients with
breast cancer
,
lysozyme
activity in undiluted and diluted sera was determined. Blood was collected from peripheral vein before surgical intervention, during surgery from vein draining when radiotherapy was finished. In parallel experiments the
lysozyme
activity was tested in peripheral blood of 40 healthy persons. Increased
lysozyme
activity both in undiluted and diluted sera was observed and radiotherapy did not change the activity of the tested enzyme.
...
PMID:Serum lysozyme activity in patients with breast cancer treated by mastectomy and radiation. 647 22
1
2
3
Next >>